Clinical Trial ID:
The Clinical Impact of Coronavirus Disease 2019 (COVID-19) in Cancer and Non-Cancer Patients: an International Multicenter Collaboration
To compare the clinical course, risk factors and outcome between cancer and non-cancer patients infected with COVID-19. We will evaluate the hospital admission rates, length of stay, ICU admission rates, rates of acute respiratory distress syndrome (ARDS), rate of requirement of mechanical ventilation and 30 day overall mortality and COVID-related mortality rates.
This is will be an international multicenter retrospective study that will include all patients diagnosed with COVID-19 from December 2019 to end of season.
Other Respiratory and Intrathoracic Organs
Baptist MD Anderson Cancer Center
Patients with a confirmed diagnosis of COVID-19 by Real-time polymerase chain reaction (RT-PCR) for SAR-COV-2 or other acceptable test.
All ages will be included (pediatrics and adults). They will be stratified in the following categories according to their age:
o < 15 years old (YO)
o 15-50 YO
o 51-70 YO
o >70 YO
Patients will be divided into those with prior diagnosis of cancer and no diagnosis of cancer for analysis purposes.
Patients with suspected diagnosis of COVID-19 (without confirmatory Real-time polymerase chain reaction (RT-PCR) for SAR-COV-2) will not be included.
Secondary Trial ID Number
Multicenter Retrospective COVID-19